Maggie Hassan. The setup forced many users to pay higher prices and allowed the British drugmaker to avoid paying Medicaid rebates, the report says.

A major pharmaceutical company ended price hikes and monopoly protection over a life-saving asthma inhaler following two years of pressure from U.S. Sen. Maggie Hassan, D-N.H. Without warning in ...

After GSK replaced a popular asthma inhaler with an identical product at a higher price, families reported substantial ...

WASHINGTON, June 27 (Reuters) - U.S. Senator Maggie Hassan said on Friday she is launching an investigation into British pharmaceutical giant GlaxoSmithKline's (GSK.L), opens new tab decision to ...

Hassan says for decades, the company GlaxoSmithKline blocked competitors and increased prices on their inhalers.

U.S. Senator Maggie Hassan (D-NH) is intensifying her scrutiny of GSK Plc (NYSE:GSK) over the company's decision to pull its widely used asthma inhaler, Flovent HFA, from the market. One year after ...

Ed Silverman, a senior writer and Pharmalot columnist at STAT, has been covering the pharmaceutical industry for nearly three decades. He is also the author of the morning Pharmalittle newsletter and ...

GlaxoSmithKline is recalling more than 590,000 albuterol inhalers. Three lots of Ventolin HFA 200D inhalers have been voluntarily recalled due to potential issues with the delivery system, a spokesman ...

Propeller Health, a company that trains its digital eye on respiratory medicine, first partnered with GSK in 2015. Now, that collaboration is being expanded -- enabling both companies to prepare for, ...

Fluticasone Propionate, an authorized generic version of asthma medication Flovent, sits on a table in nasal spray form. (Photo by _bubby_, CC BY 2.0, via Courthouse News) PHOENIX (CN) — A lawsuit ...

GlaxoSmithKline launched a voluntary recall of more than 593,000 asthma inhalers over a defect that could prevent them from releasing accurate medication doses, reports Reuters. Here are five things ...

Boehringer Ingelheim GmbH’s and Astrazeneca plc’s implementation of a $35 monthly U.S. price cap on inhalers for asthma and chronic obstructive pulmonary disease is adding to the pressure on Prasco ...